Endocrine Abstracts

Tolvaptan (TV), an ADH V2-receptor blocker, is useful in treating SIADH-induced hyponatremia. Maximum aquaresis following 15 mg TV occurs on day 1, when excess body water is greatest. This can cause a sharp rise in natremia, and poses a risk of overcorrection. Our aim was to evaluate an initial dose of 7.5 mg.Methods: We studied 7 hospitalized patients with SIADH (4 females), median age 80 (57–95), with nadir natremias (Nap) ranging from ...